Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genethon S.A.
Headquarters: Evry, Cedex, France
Website: http://www.genethon.fr
Year Founded: 1990
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Feb 4, 2025
Product Development
Gene editing companies to gain from FDA’s platform designation update
An upcoming eligibility expansion a gene editing opportunity, but leaves AAVs in the dark
BioCentury | Jan 28, 2025
Deals
Abbvie seeks molecular glue degraders from Neomorph
Also in BioCentury’s Deals Report, Novo licenses BACH1 inhibitor from Immvention, Arrivent-Lepu in ADC deal, and Sage rejects Biogen’s bid
BioCentury | Nov 25, 2024
Product Development
Elevidys isn’t slowing innovation in DMD gene therapy
Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition
BioCentury | Nov 21, 2024
Deals
Still seeking smaller bolt-ons, Novartis takes out gene therapy play Kate
Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies
BioCentury | Jun 21, 2024
Regulation
Broad label for Sarepta’s Elevidys as prospects dim for a second DMD gene therapy
FDA grants full approval to therapy for Duchenne muscular dystrophy patients ages four and up
BioCentury | May 3, 2024
Discovery & Translation
CAR T cells: Cancer, autoimmunity, and beyond?
ASGCT abstracts highlight applications for CAR Ts outside of cancer
BioCentury | May 19, 2023
Product Development
Will a gene therapy approval in DMD harm innovation?
A deep pipeline of gene therapy candidates follows Sarepta’s SRP-9001, meaning patients may face a tough choice
BioCentury | Sep 23, 2022
Discovery & Translation
Neonatal disease interception for Huntington disease; two self-assembling vaccines and more
BioCentury’s roundup of translational news
BioCentury | Jul 7, 2022
Product Development
Gene therapy’s other immune toxicity problem
In an unusual step, AAV developers are joining forces to address an old risk that DMD studies have put back in play
Items per page:
1 - 10 of 29